In-hospital Medications
Table 2 shows the different medications utilized during the study
period, many of which were part of clinical trials, at our institution.
Almost 60% of patients were treated with systemic steroids and 73%
were receiving therapeutic anticoagulation. Hydroxychloroquine,
tocilizumab and remdesivir were used in 61%, 39% and 9% of patients
respectively. There were no mortality differences in the use of
COVID-19-specific treatments, however there was a significantly higher
use of vasopressor medications in patients who died (73% vs 40%;p = 0.0002). 29% of all patients were on angiotensin converting
enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) and while not
statistically significant, there was a trend towards more patients on
ACEi/ARB and increased mortality (40% versus 24%; p = 0.06).